New approaches to molecular monitoring in CML (and other diseases)
Jerald Radich1,2, Cecilia Yeung1,2, David Wu2
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.
Abstract:
Chronic myeloid leukemia (CML) is the model cancer, demonstrating the clinical benefits of targeted therapy and the power of molecular diagnostics and monitoring. In CML, the BCR-ABL1 fusion gene and its companion messenger RNA offers a unique target differentiating cancer from the normal cell, affording the potential for very sensitive and specific assays. Because CML is such an ideal model, new methods are arising that should make testing in CML faster, more reliable, and reach a greater sensitivity. New ultrasensitive sequencing approaches, coupled with single-cell genomic approaches, further the study of measurable residual disease, clonal heterogeneity, and promise to make clinical trials more innovative and informative. These methods should be able to be transferred to other hematological and solid malignancies.
Insights
Chronic myeloid leukemia (CML) research benefits from targeted therapy and advanced molecular diagnostics. New ultrasensitive sequencing and single-cell genomics improve CML testing sensitivity and inform future cancer research.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genomics
Background:
- Chronic myeloid leukemia (CML) serves as a paradigm for targeted cancer therapy.
- The BCR-ABL1 fusion gene is a specific target for CML diagnosis and monitoring.
- Advances in molecular diagnostics are crucial for improving cancer treatment outcomes.
Purpose of the Study:
- To highlight the impact of targeted therapy and molecular diagnostics in CML.
- To introduce novel ultrasensitive sequencing and single-cell genomic approaches for CML.
- To discuss the potential of these new methods for other malignancies.
Main Methods:
- Utilizing ultrasensitive sequencing technologies.
- Employing single-cell genomic analysis.
- Developing highly sensitive and specific molecular assays.
Main Results:
- New methods promise faster and more reliable CML testing.
- Enhanced sensitivity in detecting minimal residual disease.
- Potential for more innovative and informative clinical trials.
Conclusions:
- CML is an ideal model for advancing cancer diagnostics and therapeutics.
- Ultrasensitive and single-cell genomic methods offer significant improvements for CML.
- These advanced techniques have broad applicability to other cancers.
More Related Videos
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
